个体化新抗原疫苗的临床研究进展  

Advances in the clinical research of personalized neoantigen vaccines

作　　者：吴秋吉 李秋[1] WU Qiuji;LI Qiu(Department of Medical Oncology,Cancer Center,West China Hospital,Sichuan University,Chengdu 610041,P.R.China)

机构地区：[1]四川大学华西医院肿瘤中心,成都610041

出　　处：《中国普外基础与临床杂志》2022年第8期1006-1017,共12页Chinese Journal of Bases and Clinics In General Surgery

摘　　要：免疫疗法的发展彻底改变了肿瘤治疗的格局。个体化新抗原疫苗是一种具有吸引力的全身性免疫疗法,可触发针对具有高度特异性新抗原的T细胞反应,诱导辅助性和细胞毒性T淋巴细胞的活化以增强抗肿瘤免疫。基于生物信息学的快速发展和测序技术的不断更新,新抗原疫苗得到了快速地发展,研究者们得以在不同的瘤种中进行新抗原疫苗单独或者联合治疗价值的探索。本文概述了制备个体新抗原疫苗的复杂过程,讨论了在肿瘤患者中进行个体化新抗原疫苗的临床研究的现状,对这种新颖的、个体化的免疫治疗方法的未来进行了展望。The development of immunotherapy has revolutionized the landscape of cancer treatment.Personalized neoantigen vaccines are attractive systemic immunotherapies that trigger specific T-cell responses against highly specific neoantigens,and activate and expand helper and cytotoxic T-lymphocytes to enhance anti-tumor immunity.Based on the rapid development of bioinformatics and the continuous update of sequencing technology,cancer immunotherapy with tumor neoantigens has made promising breakthroughs and progress.Researchers are exploring the value of neoantigen vaccines alone or in combination in different tumor types.We provide an overview of the complex process that is necessary to generate a personalized neoantigen vaccine,discuss the current status of clinical studies and application testing personalized neoantigen vaccines in patients with cancer and future perspectives on this novel,personalized approach to immunotherapy.

关 键 词：新抗原 疫苗 免疫疗法 临床应用 

分 类 号：R730.51[医药卫生—肿瘤]